Basic Organization Information
Multidisciplinary Association For Psychedelic Studies
- Also Known As:
- Physical Address:
Santa Cruz, CA
- Web URL:
- NTEE Category:
H Medical Research
H99 Other Medical Research N.E.C.
F Mental Health, Crisis Intervention
F30 Mental Health Treatment
R Civil Rights, Social Action, Advocacy
R05 Research Institutes and/or Public Policy Analysis
- Year Founded:
- Ruling Year:
MAPS' mission is to treat conditions for which conventional medicines provide limited relief by developing psychedelics and marijuana into prescription medicines; to treat many thousands of people by building a network of clinics where treatments can be provided; and to educate the public honestly about the risks and benefits of psychedelics and marijuana.
Dr. Rick Doblin, Ph.D.
MAPS Founder and Executive Director Rick Doblin received a Ph.D. in Public Policy in 2001 from Harvard's Kennedy School of Government, where he also obtained a Master's in Public Policy in 1990. His dissertation was on the regulation of the medical use of psychedelics and marijuana, and is posted on the MAPS website. Rick has studied with Dr. Stan Grof and was in the first group to become certified as Grof Holotropic Breathwork practitioners. He has published several papers, including a follow-up study to Walter Pahnke's Good Friday experiment and Timothy Leary's Concord Prison experiment. He is married to Lynne Jones Doblin, and they have 3 children, Eden, Lilah, and Eliora.
It has taken work across several generations, and will likely require several generations more, to realize the mission of the Multidisciplinary Association for Psychedelic Studies (MAPS), which I started 27 years ago in 1986. However, we are making great progress on achieving our goals.
We have seven studies of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) initiated or in the final stages of the approval process. We are sponsoring Phase 2 pilot studies in South Carolina, Colorado, Canada, and Israel, along with a Phase 1 psychotherapist training protocol, and a Phase 2 Relapse Study. We anticipate holding our crucial End-of-Phase 2 meeting with the FDA in about two years. In this meeting we will plan our pivotal multi-site Phase 3 studies designed to gather proof of safety and efficacy required for prescription approval for MDMA-assisted psychotherapy for PTSD.
MAPS continues to receive positive coverage of its work in major media outlets, and reaches thousands of people through its website, Bulletin, and MAPS published books and events. In April 2013, MAPS hosted its third international psychedelic research conference, which drew 1,900 attendees from 33 countries, attracted major media attention and provided a place for researchers to share their most recent findings with each other and the general public. Our psychedelic harm reduction program has provided volunteer training and services for individuals having difficult experiences in Portugal, Central America, South Africa and the US, in the last year alone.
The momentum is building. We have an incredible amount of work to do, but with the help of the international community we are closer than ever to accomplishing our goals and helping create a world where psychedelics are safely and legally available for beneficial use, and where research is governed by rigorous scientific evaluation of their risks and benefits.
Officers for Fiscal Year (IRS Form 990)
Highest Paid Employees & Their Compensation (IRS Form 990)
Highest Paid Employee data is not available for this organization.
- Population Served:
Since 2000, MAPS has disbursed over four million dollars to worthy research and educational projects. MAPS' major project is our 21-year effort to conduct MDMA-assisted psychotherapy research, which has just reached fruition. Now that the US, Swiss and Israel MDMA/PTSD protocols are fully approved, MAPS is finally starting our $5 million, 5 year plan to conduct the research necessary to submit data to FDA requesting prescription approval for MDMA-assisted psychotherapy for PTSD. MAPS has already raised over $800,000 for the MDMA/PTSD study. We are now seeking to raise $100,000 to complete our US MDMA/PTSD study,$65,000 for our Israeli MDMA/PTSD study,$50,000 for our Swiss MDMA/PTSD study, and $100,000 for our Swiss LSD/end-of-life anxiety study. MAPS is also seeking to develop marijuana into an FDA-approved medicine but first we need to obtain an independent source of supply (which we are trying to do at UMass Amherst). NIDA's monopoly on supply obstructs research and on 2-12-7 we have won a DEA Administrative Law Judge (ALJ) lawsuit against DEA to give a license to the UMass Amherst facility. However, DEA still must issue a final ruling in response to the ALJ recommendation. The other necessary step prior to the initiation of a $5 million, 5 year plan for marijuana is FDA-approval for the use of a vaporizer in clinical research. This step has been accomplished, even though for the last 4 years NIDA has refused to sell us 10 grams (!) of marijuana for further vaporizer research. MAPS also focuses on public education through our website and Bulletin and media contacts. In addition to reporting on the latest research in both the US and abroad, the tri-annual MAPS Bulletin includes feature articles, personal accounts, reports on conferences and allied organizations, and book reviews. Back issues are available on-line at:
Program Long-Term Success:
Completed treating 16 out of 20 subjects in MAPS' FDA-approved study of the use of MDMA-assisted psychotherapy in people with chronic, treatment-resistant post-traumatic stress disorder(PTSD). This is the first legal, FDA-approved study of any therapeutic use of MDMA since MDMA was criminalized in 1985.
Program Short-Term Success:
Program Success Monitored by:
Program Success Examples:
Contractor data is available for this organization!
Independent Contractor information for 2012, 2011, 2010 is available for this organization with a subscription to GuideStar Premium Pro.
GuideStar Premium Pro also includes:
- Comprehensive financial data, including functional expense detail, for every digitized fiscal year in GuideStar's database
- Ability to download up to 55 fields of data for up to 1,000 organizations at a time and up to five years worth of Income Statement
and Balance Sheet data for individual organizations
- Comprehensive advanced search capabilities, including criteria for functional expenses, investible assets, investment income
and audit & 990T filing requirements
- Ability to save organizations and searches for quick reference
- People search with salary range data
- Access to all available Forms 990
Impact Summary from the Nonprofit
MAPS primary project is to investigate MDMA-assisted psychotherapy as a novel treatment for PTSD in clinical trials conducted under U.S. FDA regulations. Our goal is to ease the suffering of many thousands of people worldwide who have experienced psychological trauma.